OncoMatch/Clinical Trials/NCT06934889
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Is NCT06934889 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ERAS-801 and ABBV-637 for glioblastoma.
Treatment: ERAS-801 · ABBV-637 · ABBV-155 · Temozolomide — The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: IDH1 wild-type
Disease stage
Required: Stage IV (WHO 2021)
Grade: IV (WHO 2021)
WHO Grade IV Glioblastoma/Gliosarcoma using WHO 2021 criteria
Prior therapy
Must have received: radiation therapy
recurrent patients must be progressive or recurrent following radiation therapy +/- chemotherapy
Cannot have received: EGFR-targeted therapy
Exception: Patients would only be eligible if surgery on a recurrence after the EGFR-targeted therapy confirmed persistence of an EGFR alteration.
Patients with prior therapy with EGFR targeting agents are ineligible because treatment with EGFR kinase inhibitors or other EGFR-targeted agents has the potential to deplete the tumor of EGFR-amplified or EGFR mutant cell populations and confound the evaluation of the investigational regimen. Patients would only be eligible if surgery on a recurrence after the EGFR-targeted therapy confirmed persistence of an EGFR alteration.
Cannot have received: investigational agent
Patients may not be receiving any other investigational agents.
Lab requirements
Blood counts
Absolute neutrophil count >1,200/mcL; Platelets >100,000/mcL; Hemoglobin > 9 g/dL
Kidney function
Creatinine ≤ institutional upper limit of normal OR Creatinine clearance >60 ml/min/1.73m2 for patients with creatinine levels above institutional normal
Liver function
Total bilirubin ≤ institutional upper limit of normal, or ≤ 3.0 mg/dL for subjects with Gilbert's syndrome; AST (SGOT) and ALT (SGPT) ≤ 3 × institutional upper limit of normal
Cardiac function
Echocardiogram with ejection fraction ≥ 50% and no other clinically significant finding; 12-lead ECG with QTc < 450 msec (Fridericia's correction), and no clinically significant abnormalities
Patients must have the following organ and marrow function: Absolute neutrophil count >1,200/mcL; Platelets >100,000/mcL; Hemoglobin > 9 g/dL. Total bilirubin ≤ institutional upper limit of normal, or ≤ 3.0 mg/dL for subjects with Gilbert's syndrome. AST (SGOT) and ALT (SGPT) ≤ 3 × institutional upper limit of normal. Creatinine ≤ institutional upper limit of normal OR Creatinine clearance >60 ml/min/1.73m2 for patients with creatinine levels above institutional normal. APTT/PTT ≤ 1.5 x institutional upper limit of normal. Echocardiogram with ejection fraction ≥ 50% and no other clinically significant finding. 12-lead electrocardiogram with QTc < 450 msec (Fridericia's correction), and no clinically significant abnormalities.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami (Data collection only) · Miami, Florida
- Indiana University (Data Collection Only) · Indianapolis, Indiana
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify